An AllTrials project

NCT03585270: A reported trial by Idorsia Pharmaceuticals Ltd.

This trial has reported on time, in line with the regulations.

Full data

Full entry on ClinicalTrials.gov NCT03585270
Title A Prospective, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 3 Study to Assess the Efficacy and Safety of Clazosentan in Preventing Clinical Deterioration Due to Delayed Cerebral Ischemia (DCI), in Adult Subjects With Aneurysmal Subarachnoid Hemorrhage (aSAH)
Results Status Reported
ACT or pACT? This is what FDAAA officially calls an "Applicable Clinical Trial"
Start date Feb. 3, 2019
Completion date June 13, 2022
Required reporting date June 13, 2025, midnight
Actual reporting date Nov. 14, 2023
Date last checked at ClinicalTrials.gov Feb. 9, 2024
Days late None